Lilly faces Zyprexa class action brought by third-party payers
This article was originally published in Scrip
Executive Summary
A federal judge in New York has granted class action status to a suit filed by insurers, labour unions and pension funds, alleging that Lillywithheld information on Zyprexa (olanzapine) adverse events and disseminated misinformation about its safety and efficacy, and marketed it for uses for which is was not indicated and for patients who would have been better served by less expensive medications.